Lumos Pharma, Inc.
LUMO
$0.00
Change (1 day)
$4.58
Year High
$1.37
Year Low
Categories
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
P/S ratio for Lumos Pharma, Inc. (LUMO)
P/S ratio as of 2023: 12.63
According to Lumos Pharma, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 12.63. At the end of 2022 the company had a P/S ratio of 19.85.
P/S ratio history for Lumos Pharma, Inc. from 2007 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 12.63 |
| 2022 | 19.85 |
| 2021 | 251.12 |
| 2020 | 1440.71 |
| 2019 | 0.39 |
| 2018 | 5.21 |
| 2017 | 72.33 |
| 2016 | 9.39 |
| 2015 | 3.20 |
| 2014 | 0.74 |
| 2013 | 56.55 |
| 2012 | 17.11 |
| 2011 | 2.53 |
| 2010 | 5.44 |
| 2009 | 12.11 |
| 2008 | 17.86 |
| 2007 | 0.00 |